Exclusive Details About 23andMe’s Partnership with GSK
23andMe and GSK signed a 4-year deal to combine their respective assets in order to identify novel drug targets, enable faster progression of clinical programs, and tackle new subsets of diseases. 23andMe welcomes all customers who’d like to participate in future research projects. Read more about this exciting collaboration in this article.